Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07249346 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation

StatusRecruiting
PhasePhase 2
Started2026-01-14
View on ClinicalTrials.gov ↗

Amendment history

2026-08-31
Study Status, Contacts/Locations v3
Start dateestimated 2026-06-01→confirmed 2026-01-14
Study sites1→3
2025-12-23
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v2
Trial statusNot Yet Recruiting→Recruiting
Study sitesdetails revised at 1 of 1 site
2025-12-17
Study Status v1
Primary completion date2027-12-01→2027-06-01
Completion date2027-12-01→2027-06-01
Start date2025-12-01→2026-06-01
2025-11-18
Original filing
This is an open label, non-randomized, multicenter, pilot, dose expansion study of low dose post-transplant cyclophosphamide (25 mg/kg on Days +3 and +4)/tacrolimus/ruxolitinib in the setting of myeloablative conditioning (MAC) allogeneic peripheral blood stem cell transplantation (PBSCT).
Trial Details
NCT Number NCT07249346
Lead Sponsor Hannah Choe, MD
Collaborators: Incyte Corporation
Conditions Leukemia, Myelodysplasia, Chronic Myelomonocytic Leukemia
Enrollment 124 participants
Start Date 2026-01-14
Primary Completion 2027-06-01 (estimated)
Study Completion 2027-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-09-02